LEADER 05555nam 22008175 450 001 9910437851703321 005 20200630171552.0 010 $a3-642-38664-4 024 7 $a10.1007/978-3-642-38664-0 035 $a(CKB)3710000000024377 035 $a(EBL)1466334 035 $a(OCoLC)862048913 035 $a(SSID)ssj0001049041 035 $a(PQKBManifestationID)11668848 035 $a(PQKBTitleCode)TC0001049041 035 $a(PQKBWorkID)11015080 035 $a(PQKB)11601329 035 $a(DE-He213)978-3-642-38664-0 035 $a(MiAaPQ)EBC1466334 035 $a(PPN)176112685 035 $a(EXLCZ)993710000000024377 100 $a20131004d2013 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aPharmacotherapy of Pulmonary Hypertension /$fedited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch 205 $a1st ed. 2013. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2013. 215 $a1 online resource (569 p.) 225 1 $aHandbook of Experimental Pharmacology,$x0171-2004 ;$v218 300 $aDescription based upon print version of record. 311 $a3-642-38663-6 320 $aIncludes bibliographical references and index. 327 $aPreface.- Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies     Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions. 330 $aThis volume focuses on current evidence-based pharmacological treatments of various forms of pulmonary hypertension and provides a comprehensive review of the latest developments in this area. The first part of the book covers the definition, classification, pathophysiology, pathology, biomarkers and animal models of the disease, thus laying the conceptual basis for what follows. The middle section provides an overview of the established therapies, such as calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and inhaled nitric oxide. The last section explores novel pathways and emerging therapeutic approaches including soluble guanylate cyclase stimulators, Rho-kinase inhibitors, inhibitors of serotonin receptors and transporters, peptide growth factors, vasoactive peptides, modulators of redox equilibrium and cyclic nucleotide homeostasis, as well as immunosuppressive and anti-proliferative agents. Particular attention is given to the clinical applications of these experimental therapies, that are on the horizon. The book thus spans the continuum from basic science to clinical applications. 410 0$aHandbook of Experimental Pharmacology,$x0171-2004 ;$v218 606 $aPharmacology 606 $aPharmaceutical technology 606 $aInternal medicine 606 $aRespiratory organs?Diseases 606 $aLaboratory medicine 606 $aMolecular biology 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 606 $aPneumology/Respiratory System$3https://scigraph.springernature.com/ontologies/product-market-codes/H33134 606 $aLaboratory Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B15007 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 615 0$aPharmacology. 615 0$aPharmaceutical technology. 615 0$aInternal medicine. 615 0$aRespiratory organs?Diseases. 615 0$aLaboratory medicine. 615 0$aMolecular biology. 615 14$aPharmacology/Toxicology. 615 24$aPharmaceutical Sciences/Technology. 615 24$aInternal Medicine. 615 24$aPneumology/Respiratory System. 615 24$aLaboratory Medicine. 615 24$aMolecular Medicine. 676 $a615.5/8 676 $a618.922004636 702 $aHumbert$b Marc$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aEvgenov$b Oleg V$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aStasch$b Johannes-Peter$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910437851703321 996 $aPharmacotherapy of pulmonary hypertension$91078373 997 $aUNINA